Filing Flows › AbCellera Biologics (ABCL) › Q4 2025
AbCellera Biologics (ABCL) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 24, 2026
AbCellera Biologics (ABCL) reported revenue of $44.9M for the fourth quarter 2025 (Q4 2025), +788% from a year earlier and +401% from the quarter before. Operating margin was -63.7%, net loss $8.9M (19.9% of revenue).
AbCellera Biologics, Q4 2025: revenue $44.9M (+788% year over year), operating margin -63.7%, net loss $8.9M, operating cash flow −$34.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $44.9M | +401% | +788% |
| Operating profit | −$28.6M | — | — |
| Net earnings | −$8.9M | — | — |
| Operating cash flow | −$34.7M | — | — |
What changed
Revenue was $44.9M in Q4 2025, up 788% year over year and up 401% from the previous quarter. Licensing and royalty revenue was the largest line at 81% of revenue.
Operating costs exceeded revenue by $28.6M, an operating margin of -63.7%. Total costs fell 6% while revenue rose 788%. The quarter ended with a net loss of $8.9M, narrower than the previous quarter's $57.1M loss. Non-operating items added $9.1M, -47% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$34.7M. Non-cash charges added back $6.1M of depreciation and amortization and $12.9M of share-based compensation. Working capital and other items used $44.8M. Capital expenditures of $9.8M exceeded it, leaving free cash flow of −$44.6M.
Questions
What was AbCellera Biologics' revenue in the fourth quarter 2025?
AbCellera Biologics (ABCL) reported revenue of $44.9M for the fourth quarter 2025 (Q4 2025), +788% from a year earlier and +401% from the quarter before.
Was AbCellera Biologics profitable in the fourth quarter 2025?
Operating loss was $28.6M (-63.7% of revenue) and net loss $8.9M.